View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 28, 2020

Sanofi and Regeneron’s trial to continue in critical Covid-19 patients

Sanofi and Regeneron Pharmaceuticals are set to continue the Phase II/III clinical trial of Kevzara (sarilumab) in hospitalised patients having critical respiratory illness caused by Covid-19.

The move is based on a recommendation by the Independent Data Monitoring Committee (IDMC), which reviewed available Phase II and Phase III findings.

Sanofi and Regeneron will immediately amend the trial protocol to enrol only critical patients in 400mg Kevzara or placebo arms, and a 200mg dose of the drug will be discontinued.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena